Company profile

Biosplice Therapeutics

Biosplice Therapeutics, founded in 2008 and headquartered in San Diego, California, has raised approximately $778 million from investors including aMoon Fund, Eventide, SymBiosis II, Sands Capital, and Verition Fund Management. The company develops first-in-class small-molecule therapeutics by modulating alternative pre-mRNA splicing to treat degenerative and disease conditions such as osteoarthritis, oncology, and neurological disorders. A major $120 million venture funding round in 2021 supported advancement of its lead clinical programs and expansion of its therapeutic pipeline. With strong scientific backing and funding support, Biosplice is positioned to innovate in the next generation of biotech therapies.

Back to profiles

Quick facts

Total funding: $778 million
Founded: 2008
Headquarters: San Diego, California

Notable investors

Eventide
SymBiosis II
Sands Capital
Verition Fund Management

Reach buyers like Biosplice Therapeutics on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Biosplice Therapeutics
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Biosplice Therapeutics.

The 14-day trial ships every feature, no card required.

Start free →